Your browser doesn't support javascript.
Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants.
Tamura, Tomokazu; Ito, Jumpei; Uriu, Keiya; Zahradnik, Jiri; Kida, Izumi; Anraku, Yuki; Nasser, Hesham; Shofa, Maya; Oda, Yoshitaka; Lytras, Spyros; Nao, Naganori; Itakura, Yukari; Deguchi, Sayaka; Suzuki, Rigel; Wang, Lei; Begum, Mst Monira; Kita, Shunsuke; Yajima, Hisano; Sasaki, Jiei; Sasaki-Tabata, Kaori; Shimizu, Ryo; Tsuda, Masumi; Kosugi, Yusuke; Fujita, Shigeru; Pan, Lin; Sauter, Daniel; Yoshimatsu, Kumiko; Suzuki, Saori; Asakura, Hiroyuki; Nagashima, Mami; Sadamasu, Kenji; Yoshimura, Kazuhisa; Yamamoto, Yuki; Nagamoto, Tetsuharu; Schreiber, Gideon; Maenaka, Katsumi; Hashiguchi, Takao; Ikeda, Terumasa; Fukuhara, Takasuke; Saito, Akatsuki; Tanaka, Shinya; Matsuno, Keita; Takayama, Kazuo; Sato, Kei.
  • Tamura T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Ito J; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan.
  • Uriu K; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Zahradnik J; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Kida I; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Anraku Y; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Nasser H; First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia.
  • Shofa M; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Oda Y; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Lytras S; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Nao N; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
  • Itakura Y; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
  • Deguchi S; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan.
  • Suzuki R; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Wang L; Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow, UK.
  • Begum MM; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Kita S; One Health Research Center, Hokkaido University, Sapporo, Japan.
  • Yajima H; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan.
  • Sasaki J; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Sasaki-Tabata K; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
  • Shimizu R; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Tsuda M; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan.
  • Kosugi Y; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Fujita S; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Pan L; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Sauter D; Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Yoshimatsu K; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Suzuki S; Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
  • Asakura H; Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
  • Nagashima M; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
  • Sadamasu K; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Yoshimura K; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Yamamoto Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Nagamoto T; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Schreiber G; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Maenaka K; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Hashiguchi T; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
  • Ikeda T; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Fukuhara T; Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany.
  • Saito A; Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
  • Tanaka S; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Matsuno K; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan.
  • Takayama K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
  • Sato K; Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Nat Commun ; 14(1): 2800, 2023 05 16.
Article in English | MEDLINE | ID: covidwho-2326577
ABSTRACT
In late 2022, SARS-CoV-2 Omicron subvariants have become highly diversified, and XBB is spreading rapidly around the world. Our phylogenetic analyses suggested that XBB emerged through the recombination of two cocirculating BA.2 lineages, BJ.1 and BM.1.1.1 (a progeny of BA.2.75), during the summer of 2022. XBB.1 is the variant most profoundly resistant to BA.2/5 breakthrough infection sera to date and is more fusogenic than BA.2.75. The recombination breakpoint is located in the receptor-binding domain of spike, and each region of the recombinant spike confers immune evasion and increases fusogenicity. We further provide the structural basis for the interaction between XBB.1 spike and human ACE2. Finally, the intrinsic pathogenicity of XBB.1 in male hamsters is comparable to or even lower than that of BA.2.75. Our multiscale investigation provides evidence suggesting that XBB is the first observed SARS-CoV-2 variant to increase its fitness through recombination rather than substitutions.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Topics: Variants Limits: Animals / Humans / Male Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2023 Document Type: Article Affiliation country: S41467-023-38435-3

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Randomized controlled trials Topics: Variants Limits: Animals / Humans / Male Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2023 Document Type: Article Affiliation country: S41467-023-38435-3